Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
First subject dosed with Nykode Therapeutics’ T cell focused SARS-CoV-2 vaccine candidate. This is part of the ongoing phase 1/2...